


Expected submission timelines⁽¹⁾

Pipeline charts as communicated at Q2 2021 Results Meeting dated JULY 29, 202

NMEs

Additional Indications



- Immuno-inflammation
- Oncology
- Rare Diseases
- Rare Blood Disorders
- Neurology
- Vaccines

As of June 30, 2021, barring unforeseen events

- (1) Excluding Phase 1 (without POC)
- (2) Projects within a specified year are not arranged by submission timing
- (3) Developed in collaboration with Regeneron
- (4) Developed in collaboration with GSK and with funding from Biomedical Advanced Research and Development Authority (BARDA)
- (5) Developed in collaboration with Translate Bio
- (6) Developed in collaboration with Sobi
- (7) Developed in collaboration with AstraZeneca
- (8) Enzyme replacement therapy

RMS: Relapsing multiple sclerosis, PP: Primary progressive; SP: Secondary progressive ; ITP: Immune Thrombocytopenia ; MM: Multiple myeloma; CSCC: cutaneous squamous cell carcinoma; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; COPD: chronic obstructive pulmonary disease; Te: transplant eligible; Ti transplant ineligible; ped: pediatric; NSCLC: non-small cell lung cancer; mBC: metastatic breast cancer; ASMD: acid sphingomyelinase deficiency; ad+ped: adults and pediatric